• Thurs news: Lilly’s weight-loss drug prevents diabetes. Merck pays $588M for bispecific. Amgen speaks out about bone density issues with obesity drug. PTC gets gene therapy approval. JNJ’s 340B legal fight. See more on our front page

Gentiva's new suitor?









Looks like you may be right. Kindred increased offer to match at $17.25 / share. I think when they get in that $18 - $19 range, you may see some real movement, depending on Kindred's willingness to take on Gentiva's executive management team as partners.
 








Anyone who doesn't think that Kindred will end up owning Gentiva is not paying attention. My concern is this: Once Kindred acquires Gentiva will it adopt the home health programs i.e. safe strides, or reinvent the wheel? What will the finished product look like and how will it sell in the market?
 








Any news on potential buyout. I m trying to decide whether to accept offer at Gentiva( should I try to negotiate higher offer than initially presented?). Or accept offer at pharma company that is having financial problems. Both are going to be high pressure but pharma sales is 9-5 because offices close at 5pm . I hate being micro managed and thrive when I know I am doing a good job....is Gentiva going to beat me down. I like the people I interviewed with but honestly didn t spend a lot of time with them. The office I ll be with is in the southeast, and is the market leader. Any thoughts?